PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 5 months ago L'homologation par la FDA américaine du colorant bleu naturel de Fermentalg ouvre la voie à une nouvelle génération de produits biosourcés pour l'industrie agro-alimentaire Fermentalg annonce l'homologation de son colorant bleu naturel par la FDA américaine, une avancée majeure pour l'industrie alimentaire. La commercialisation d'EverzureTM Galdieria promet des alternatives naturelles et durables FDA Industrie Alimentaire FERMENTALG Colorant Bleu Naturel Alternative Naturelle
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 5 months ago The FDA's approval of Fermentalg's natural blue dye paves the way for a new generation of bio-based products in the food industry. Fermentalg's Everzure™ Galdieria, a natural blue dye approved by the FDA, offers innovative biosourced solution for food industry, replacing petroleum-based colorants FDA Approval Food Industry FERMENTALG Natural Blue Dye Everzure™ Galdieria
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 5 months ago Klea Holding démarre fort le deuxième trimestre 2025 avec un nouveau record en avril pour sa filiale Smart Salem Smart Salem établit un nouveau record mensuel avec 18 497 tests en avril 2025, illustrant la croissance continue de l'entreprise. Klea Holding confirme sa stratégie de développement Croissance Performance Smart Salem Klea Holding Record Mensuel
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 5 months ago Klea Holding mark strong start to Q2 2025 with new monthly record in April for its subsidiary Smart Salem Smart Salem, a subsidiary of Klea Holding, achieves a new monthly record by conducting 18,497 tests in April 2025, displaying a 94% year-on-year growth. Growth strategy in progress Growth Strategy Smart Salem Klea Holding Monthly Record Digitalized Medical Analysis
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 5 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 5 months ago Information financière trimestrielle / Information financière du premier trimestre Hausse des taux d'occupation dans les maisons de retraite en France et à l'international. Croissance organique du chiffre d'affaires de +6,2% au premier trimestre 2025, avec 1 Md€ de cessions sécurisées à fin avril Chiffre D'affaires Croissance Organique Taux D'occupation Cessions Perspectives 2025
PRESS RELEASE published on 05/12/2025 at 07:10, 1 year 5 months ago Hypoport starts 2025 with strong earnings in Q1 Hypoport SE reports strong earnings in Q1/2025 with 19% revenue growth and 88% rise in EBIT. Real Estate & Mortgage Platforms drive performance Revenue Growth Financial Performance Hypoport SE Q1 Results Real Estate & Mortgage Platforms
PRESS RELEASE published on 05/12/2025 at 07:05, 1 year 5 months ago Solid growth in the cloud // Pinnacle Award 2025 // Geopolitical environment leads to project delays despite strong pipeline // Forecast confirmed All for One Group SE reports solid growth in cloud services despite geopolitical challenges causing project delays. Unaudited results show sales at EUR 257.6 million and dividend increased to EUR 1.60 per share. Forecast for 2024/25 confirmed Cloud Services Geopolitical Challenges Forecast All For One Group SE Project Delays
PRESS RELEASE published on 05/12/2025 at 07:00, 1 year 5 months ago AEVIS VICTORIA SA – Sustained revenue growth in operating divisions. An increase of 17.0% was recorded in the first quarter of 2025. AEVIS VICTORIA SA reports 17.0% revenue growth in Q1 2025, driven by Swiss Medical Network and MRH Switzerland AG. Expansion and acquisitions support momentum Revenue Growth Acquisitions AEVIS VICTORIA SA Swiss Medical Network MRH Switzerland AG
PRESS RELEASE published on 05/12/2025 at 07:00, 1 year 5 months ago AEVIS VICTORIA SA – Croissance soutenue du chiffre d’affaires dans les divisions opérationnelles. Augmentation de 17.0% au 1er trimestre 2025. AEVIS VICTORIA SA a enregistré une croissance soutenue de 17.0% de son chiffre d’affaires au 1er trimestre 2025. Swiss Medical Network et MRH Switzerland AG ont vu une augmentation organique de 3.2% Chiffre D’affaires Croissance Soutenue AEVIS VICTORIA SA Swiss Medical Network 1er Trimestre 2025
Published on 10/30/2026 at 23:35, 4 hours 25 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 4 hours 30 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 7 hours 13 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 9 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 12 hours 30 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 5 hours 11 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 9 hours 22 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 5 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 5 hours ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie